Literature DB >> 28024095

Recent development of transcatheter closure of atrial septal defect and patent foramen ovale with occluders.

Baiyu Tang1, Feng Su1, Xiangke Sun1, Qin Wu2, Quansheng Xing2, Suming Li3.   

Abstract

Atrial septal defect (ASD) and patent foramen ovale (PFO) are common clinical congenital heart defects. As an effective method for the treatment of ASD and PFO, transcatheter closure with occluders presents many advantages, including safety, ease of operation, minimal invasiveness, and reduced complications. This contribution reviews the various types of occluders currently used in clinical applications and under development, including non degradable occluders, partially degradable occluders, and totally degradable occluders. A number of case studies are described in detail. Comparison is made on the treatment outcomes using different occulders. Future development of transcatheter closure is discussed, in particular the use of totally degradable occluders.
© 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 433-443, 2018. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  atrial septal defect; biodegradable; occluder; patent foramen ovale

Mesh:

Year:  2016        PMID: 28024095     DOI: 10.1002/jbm.b.33831

Source DB:  PubMed          Journal:  J Biomed Mater Res B Appl Biomater        ISSN: 1552-4973            Impact factor:   3.368


  6 in total

1.  A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder.

Authors:  Yajuan Du; Hang Xie; Hui Shao; Gesheng Cheng; Xingye Wang; Xumei He; Beidi Lan; Lu He; Yushun Zhang
Journal:  Front Cardiovasc Med       Date:  2022-05-03

Review 2.  Atrial septal defect (ASD) device trans-catheter closure: limitations.

Authors:  Alessia Faccini; Gianfranco Butera
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

3.  Improvement of physical capacity in patients undergoing transcatheter closure of atrial septal defects.

Authors:  Paweł Prochownik; Tadeusz Przewłocki; Piotr Podolec; Piotr Wilkołek; Bartosz Sobień; Urszula Gancarczyk; Natalia Podolec; Monika Komar
Journal:  Postepy Kardiol Interwencyjnej       Date:  2018-03-22       Impact factor: 1.426

4.  Health-Related Quality of Life in Children and Adolescents with Simple Congenital Heart Defects before and after Transcatheter Intervention Therapy: A Single-Center Study.

Authors:  Kai-Peng Sun; Ning Xu; Shu-Ting Huang; Hua Cao; Qiang Chen
Journal:  Ann Thorac Cardiovasc Surg       Date:  2020-09-07       Impact factor: 1.520

5.  Key Regulatory Differentially Expressed Genes in the Blood of Atrial Septal Defect Children Treated With Occlusion Devices.

Authors:  Bo-Ning Li; Quan-Dong Tang; Yan-Lian Tan; Liang Yan; Ling Sun; Wei-Bing Guo; Ming-Yang Qian; Allen Chen; Ying-Jun Luo; Zhou-Xia Zheng; Zhi-Wei Zhang; Hong-Ling Jia; Cong Liu
Journal:  Front Genet       Date:  2021-12-08       Impact factor: 4.599

6.  Midterm Prognosis of Sexagenary Patients after Transcatheter Device Closure of Atrial Septal Defects: a Single-Chinese Center Experience.

Authors:  Kai-Peng Sun; Ning Xu; Shu-Ting Huang; Hua Cao; Qiang Chen
Journal:  Braz J Cardiovasc Surg       Date:  2022-03-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.